» Articles » PMID: 27109101

MMSET/WHSC1 Enhances DNA Damage Repair Leading to an Increase in Resistance to Chemotherapeutic Agents

Overview
Journal Oncogene
Date 2016 Apr 26
PMID 27109101
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

MMSET/WHSC1 is a histone methyltransferase (HMT) overexpressed in t(4;14)+ multiple myeloma (MM) patients, believed to be the driving factor in the pathogenesis of this MM subtype. MMSET overexpression in MM leads to an increase in histone 3 lysine 36 dimethylation (H3K36me2), and a decrease in histone 3 lysine 27 trimethylation (H3K27me3), as well as changes in proliferation, gene expression and chromatin accessibility. Prior work linked methylation of histones to the ability of cells to undergo DNA damage repair. In addition, t(4;14)+ patients frequently relapse after regimens that include DNA damage-inducing agents, suggesting that MMSET may play a role in DNA damage repair and response. In U2OS cells, we found that MMSET is required for efficient non-homologous end joining as well as homologous recombination. Loss of MMSET led to loss of expression of several DNA repair proteins, as well as decreased recruitment of DNA repair proteins to sites of DNA double-strand breaks (DSBs). By using genetically matched MM cell lines that had either high (pathological) or low (physiological) expression of MMSET, we found that MMSET-high cells had increased damage at baseline. Upon addition of a DNA-damaging agent, MMSET-high cells repaired DNA damage at an enhanced rate and continued to proliferate, whereas MMSET-low cells accumulated DNA damage and entered cell cycle arrest. In a murine xenograft model using t(4;14)+ KMS11 MM cells harboring an inducible MMSET shRNA, depletion of MMSET enhanced the efficacy of chemotherapy, inhibiting tumor growth and extending survival. These findings help explain the poorer prognosis of t(4;14) MM and further validate MMSET as a potential therapeutic target in MM and other cancers.

Citing Articles

The Interplay between the DNA Damage Response (DDR) Network and the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Multiple Myeloma.

Malamos P, Papanikolaou C, Gavriatopoulou M, Dimopoulos M, Terpos E, Souliotis V Int J Mol Sci. 2024; 25(13).

PMID: 39000097 PMC: 11241508. DOI: 10.3390/ijms25136991.


Epigenetic modulators provide a path to understanding disease and therapeutic opportunity.

Honer M, Ferman B, Gray Z, Bondarenko E, Whetstine J Genes Dev. 2024; 38(11-12):473-503.

PMID: 38914477 PMC: 11293403. DOI: 10.1101/gad.351444.123.


Discovery of NSD2 non-histone substrates and design of a super-substrate.

Weirich S, Kusevic D, Schnee P, Reiter J, Pleiss J, Jeltsch A Commun Biol. 2024; 7(1):707.

PMID: 38851815 PMC: 11162472. DOI: 10.1038/s42003-024-06395-z.


Mechanisms of the role of proto-oncogene activation in promoting malignant transformation of mature B cells.

Zhou R, Guo J, Feng X, Zhou W Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024; 49(1):113-121.

PMID: 38615172 PMC: 11017026. DOI: 10.11817/j.issn.1672-7347.2024.230304.


NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome.

Sobh A, Encinas E, Patel A, Surapaneni G, Bonilla E, Kaestner C Blood. 2024; 144(3):283-295.

PMID: 38598835 PMC: 11830969. DOI: 10.1182/blood.2023022859.


References
1.
Keats J, Reiman T, Maxwell C, Taylor B, Larratt L, Mant M . In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood. 2002; 101(4):1520-9. DOI: 10.1182/blood-2002-06-1675. View

2.
Englander E, Howard B . Nucleosome positioning by human Alu elements in chromatin. J Biol Chem. 1995; 270(17):10091-6. DOI: 10.1074/jbc.270.17.10091. View

3.
Palumbo A, Anderson K . Multiple myeloma. N Engl J Med. 2011; 364(11):1046-60. DOI: 10.1056/NEJMra1011442. View

4.
Mao Z, Hine C, Tian X, Van Meter M, Au M, Vaidya A . SIRT6 promotes DNA repair under stress by activating PARP1. Science. 2011; 332(6036):1443-6. PMC: 5472447. DOI: 10.1126/science.1202723. View

5.
Gaymes T, Padua R, Pla M, Orr S, Omidvar N, Chomienne C . Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis?. Mol Cancer Res. 2006; 4(8):563-73. DOI: 10.1158/1541-7786.MCR-06-0111. View